Literature DB >> 22100258

Bivalent molecular probes for dopamine D2-like receptors.

Daniela Huber1, Stefan Löber, Harald Hübner, Peter Gmeiner.   

Abstract

Merging two arylamidoalkyl substituted phenylpiperazines as prototypical recognition elements for dopamine D(2)-like receptors by oligoethylene glycol linkers led to a series of bivalent ligands. These dimers were investigated in comparison to their monomeric analogues for their dopamine D(2long), D(2short), D(3) and D(4) receptor binding. Radioligand binding experiments revealed strong bivalent effects for some para-substituted benzamide derivatives. For the D(3) subtype, the target compounds 32, 34 and 36 showed an up to 70-fold increase of affinity and a substantial enhancement of subtype selectivity when compared to the monovalent analogue 24. Analysis of the binding curves displayed Hill slopes very close to one indicating that the bivalent ligands displace 1equiv of radioligand. Obviously, the two pharmacophores occupy an orthosteric and an allosteric binding site rather than adopting a receptor-bridging binding mode.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22100258     DOI: 10.1016/j.bmc.2011.10.063

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

1.  Novel bivalent ligands for D2/D3 dopamine receptors: Significant co-operative gain in D2 affinity and potency.

Authors:  Sanjib Gogoi; Swati Biswas; Gyan Modi; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  ACS Med Chem Lett       Date:  2012-10-26       Impact factor: 4.345

2.  Design, synthesis and biological evaluation of bivalent ligands against A(1)-D(1) receptor heteromers.

Authors:  Jian Shen; Lei Zhang; Wan-ling Song; Tao Meng; Xin Wang; Lin Chen; Lin-yin Feng; Ye-chun Xu; Jing-kang Shen
Journal:  Acta Pharmacol Sin       Date:  2013-01-21       Impact factor: 6.150

Review 3.  Dopamine receptor signaling and current and future antipsychotic drugs.

Authors:  Kevin N Boyd; Richard B Mailman
Journal:  Handb Exp Pharmacol       Date:  2012

4.  2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.

Authors:  Amy Hauck Newman; Francisco O Battiti; Alessandro Bonifazi
Journal:  J Med Chem       Date:  2019-09-24       Impact factor: 7.446

5.  The dopamine D2 receptor dimer and its interaction with homobivalent antagonists: homology modeling, docking and molecular dynamics.

Authors:  Agnieszka A Kaczor; Manuela Jörg; Ben Capuano
Journal:  J Mol Model       Date:  2016-08-04       Impact factor: 1.810

Review 6.  Understanding the Role of GPCR Heteroreceptor Complexes in Modulating the Brain Networks in Health and Disease.

Authors:  Dasiel O Borroto-Escuela; Jens Carlsson; Patricia Ambrogini; Manuel Narváez; Karolina Wydra; Alexander O Tarakanov; Xiang Li; Carmelo Millón; Luca Ferraro; Riccardo Cuppini; Sergio Tanganelli; Fang Liu; Malgorzata Filip; Zaida Diaz-Cabiale; Kjell Fuxe
Journal:  Front Cell Neurosci       Date:  2017-02-21       Impact factor: 5.505

Review 7.  An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors.

Authors:  Paula Morales; Patricia H Reggio
Journal:  Cannabis Cannabinoid Res       Date:  2017-10-01

Review 8.  Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them?

Authors:  Marco Carli; Shivakumar Kolachalam; Stefano Aringhieri; Mario Rossi; Luca Giovannini; Roberto Maggio; Marco Scarselli
Journal:  Curr Neuropharmacol       Date:  2018-01-30       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.